TNFRSF18 and neoplasm: Furthermore, pre-clinical evidence on GITR-agonist monotherapy has demonstrated antitumor effect via enhancing CD8+ and CD4+ effector T-cell activity and depleting tumor-infiltrating Tregs, which are considered the main GITR expressors [26].